The Northern California Psychiatric Society echoes the American Psychiatric Association's alarm regarding the views presented at the US Food and Drug Administration (FDA)'s panel on selective serotonin reuptake inhibitors (SSRIs) in pregnancy. Misinformation can deter pregnant individuals from essential, life-saving care, despite the perinatal period's high risk for worsening mood and anxiety disorders, where untreated maternal mental illness can lead to significant risks, including maternal suicide which is a leading cause of death during pregnancy and in the year after delivery. Rigorous evidence from several studies indicates that individuals may safely take SSRIs as clinically indicated during or prior to pregnancy, with no overall increased risk of birth defects. Decisions regarding SSRIs or other psychiatric medications during pregnancy should involve collaborative decision-making between patients and their physicians. We strongly urge the FDA to base its public health guidance on rigorous and balanced evidence to support maternal and fetal well-being